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Abstract
Recent clinical trials have shown that in vivo and ex vivo gene therapy strategies can be an
option for the treatment of several neurological disorders. Both strategies require efficient
and safe vectors to 1) deliver the therapeutic gene directly into the CNS or 2) to genetically
modify stem cells that will be used as Trojan horses for the systemic delivery of the thera-
peutic protein. A group of target diseases for these therapeutic strategies are mitochondrial
encephalopathies due to mutations in nuclear DNA genes. In this study, we have developed
a lentiviral vector (CCoq9WP) able to overexpress Coq9mRNA and COQ9 protein in
mouse embryonic fibroblasts (MEFs) and hematopoietic progenitor cells (HPCs) from
Coq9R239X mice, an animal model of mitochondrial encephalopathy due to primary Coen-
zyme Q (CoQ) deficiency. Ectopic over-expression of Coq9 in both cell types restored the
CoQ biosynthetic pathway and mitochondrial function, improving the fitness of the trans-
duced cells. These results show the potential of the CCoq9WP lentiviral vector as a tool for
gene therapy to treat mitochondrial encephalopathies.
Introduction
Mitochondrial diseases are a heterogeneous group of rare diseases that generally affect mito-
chondrial oxidative phosphorylation (OXPHOS) system directly or indirectly. These disorders
can be due to mutations in mitochondrial DNA (mtDNA), which cause maternally sporadic
or disorders inherited through the maternal lineage, or due to mutations in nuclear DNA
(nDNA), which show a Mendelian pattern of inheritance. Because the human brain has such
high-energy dependence, almost all presentations of mitochondrial disease contain neurologic
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symptoms. Thus, mitochondrial encephalopathy is the most common neurometabolic disor-
der, but current therapies are frequently inadequate, inefficient and mostly palliative [1].
Primary Coenzyme Q10 (CoQ10) deficiency is a mitochondrial disorder that is presented in
some cases as an encephalopathic form [2], which is recapitulated in the Coq9R239X mouse
model. Coq9R239X mice have a dysfunctional COQ9 protein, which leads to a severe reduction
in COQ7, an enzyme of the CoQ biosynthetic pathway that catalyzes the hydroxylation of
demethoxyubiquinone (DMQ) to produce 5-hydroxyquinone (5-HQ) (S1 Fig) [3, 4]. As a
result, tissues from Coq9R239X mice accumulate DMQ and have a severe reduction in CoQ lev-
els, which cause a reduction in bioenergetics performance and increased oxidative damage in
the cerebrum. As a consequence, Coq9R239X mice show reactive astrogliosis and spongiform
degeneration with early death [3].
Vector-mediated gene transfer is a promising strategy to treat monogenic diseases that
affect the central nervous system (CNS). However, the blood brain barrier (BBB) can exclude
the vast majority of gene transfer vehicles from reaching the CNS via the vasculature. For this
reason, some strategies have been developed in the last decades in order to allow gene vectors
to reach the CNS. These strategies include direct delivery of gene transfer vectors, such as lenti-
virus (LVs) [5] or adeno-associated virus (AAV) [6] directly into various compartments of the
brain; or the use of ex vivo genetically modified hematopoietic stem cells (HSCs), which will
migrate into the CNS and differentiate into microglia to produce the therapeutic effects [7].
Both strategies have reached clinical trials using LVs for the treatment of Parkinson’s Disease
[8] and leukodystrophies [9, 10], respectively. The work reported by Palfi and colleagues dem-
onstrated that direct applications of LVs into the human CNS is safe and can improve the levels
of dopaminergic activity [8]. In a more robust approach, Biffy and coworkers demonstrated
that gene modified HSCs (GM-HSCs) can be an optimal trojan horse to deliver therapeutic
proteins through the body and specifically into the CNS [11, 12]. These authors showed that
transplantation of GM-HSCs was able to normalize the neuropathological alterations of
Arsa–/–mice and that the microglia derived from these GM-HSCs was the exclusive source of
the lysosomal enzyme arylsulfatase A (ARSA) in the CNS. They also observed enzyme transfer
and robust cross-correction of neural cell targets in vivo [11, 12]. Importantly, metachromatic
leukodystrophy (MLD) patients treated with LVs-ARSA-HSCs have shown impressive clinical
benefits [9, 10].
The results of Palfi and Biffi opened the possibility to use direct inoculation of LVs or trans-
plantation of GM-HSCs for the treatment of mitochondrial encephalopathies due to mutations
in nDNA genes. In this manuscript we aimed to study the feasibility of treating mitochondrial
encephalopathies by gene therapy strategies using the Coq9R239X mice as model for these dis-
eases. We therefore analyzed whether COQ9 could be overexpressed in relevant target cells,
mouse embryonic fibroblasts (MEFs) and HPCs, and study whether the ectopic expression of
this protein could restore the mitochondrial dysfunction observed in Coq9-mutant cells.
Materials and Methods
Lentiviral vectors constructs, vector production and determination of
vector copy number per cell
The CCoq9WP LV plasmid was constructed by standard cloning techniques using PstI/BamHI
restriction enzymes to replace the eGFP in the CEWP backbone [13] for the Coq9 cDNA
(obtained by gene synthesis from Genscript).
Vector production was performed as previously described [13]. Briefly, fast growing 293T
cells were plated on petri-dishes (Sarsted,Newton, NC), 24h later, the vector (CCoq9WP), the
packaging (pCMVΔR8.91) and the envelope (pMD2.G) plasmids were transfected using
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LipoD293 (SignaGen, Gainthersburg, MD, USA). The pCMVΔR8.91 and the pMD2.G plas-
mids (http://www.addgene.org/Didier_Trono) are described elsewhere [14]. Viral supernatants
were collected 48h after transfection and the particles were frozen or concentrated by ultrafil-
tration at 2000 g and 4°C, using 100 Kd centrifugal filter devices (Amicon Ultra-15, Millipore,
Billerica, MA) [15]. LVs particles supernatant were used to transduce MEF or mHPCs by add-
ing different volumes to the cell cultures in order to achieve the desired multiplicities of infec-
tion (MOI). The medium was changed after 12 hours of incubation.
Vector titration was estimated on K562 cells by incubating 105 cells with 1 μl, 10μl and
100 μl of viral supernatant. Transduced cells were lysed and DNA extracted after 7–10 days
post-transduction. Vector copy number per cell (vcn/c) was determined using Q-PCR using
the primer pair: WPRErev: 5’-cggaattgtcagtgcccaaca-3’ y WPREfw: 5’-ggtgtgcactgtgtttgctga-3’.
Control genomic DNA of K562 cells (105) were mixed with 10-fold increasing amounts of
CCoq9WP plasmid DNA (102 up to 107 copies) to establish the standard curve in each experi-
ment. Titre (Transducing units/ml) were estimated taking into account the calculated vcn/c,
the viral volume used and the initial cell number (105).
Mouse model
The Coq9R239X mouse model (http://www.informatics.jax.org/allele/key/829271) was previ-
ously generated in collaboration with Ingenious Targeting Laboratory and characterized in our
lab under mix of C57BL/6N and C57BL/6J genetic background [3, 4]. Coq9R239X/+ mice were
crossbred in order to generate Coq9+/+, Coq9R239X/+, Coq9R239X/R239X (referred in the article as
Coq9R239X). Only homozygous wild-type and mutant mice were used in the study.
Mice were housed in the Animal Facility of the University of Granada under an SPF zone
with lights on at 7:00 AM and off at 7:00 PM. Mice had unlimited access to water and rodent
chow. All experiments were performed according to a protocol approved by the Institutional
Animal Care and Use Committee of the University of Granada (procedures 92-CEEA-OH-
2015) and were in accordance with the European Convention for the Protection of Vertebrate
Animals used for Experimental and Other Scientific Purposes (CETS # 123) and the Spanish
law (R.D. 53/2013).
MEFs isolation and transduction from donor mice
MEFs from Coq9+/+ and Coq9R239X mice were grown in complete medium (high glucose
DMEM-GlutaMAX medium supplemented with 10% FBS, 1% MEM non-essential amino
acids and 1% antibiotics/antimycotic). For transduction, 0.5–1 x 105 MEFs were exposed to
increasing doses of the LVs supernatant in DMEMmedium in the absence of serum during 12
hours. After that, MEFs were cultured in complete medium during 7 to 20 days.
Bone marrow isolation and transduction from donor mice
The bone marrow was isolated from 4–6 weeks old donor mice (Coq9+/+ or Coq9R239X). Bone
marrow cells were harvested from euthanized donor mice by CO2 asphyxiation followed by
cervical dislocation. The cells were flushed out of the 2 femurs and 2 tibias under sterile condi-
tions, passed through a 40 μm cell strainer and treated with ammonium chloride solution
(Stem Cell Technologies) to eliminate the red blood cells. Cells were stained with anti-mouse
Ly-6A/E (Sca-1)-PE (eBioscience, San Diego, CA), washed with AutoMACS buffer and incu-
bated with Anti-PE MicroBeads (Miltenyi Biotec) following the manufacturer´s instructions.
An enriched mouse hematopoietic progenitor cells (HPCs) fraction was obtained after a mag-
netic separation using AutoMACS Pro Separator (Miltenyi Biotec). For transduction, 1x106
mHPCs were incubated with LVs supernatant at MOI = 200 in Stem-Span Serum-Free
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Expansion Medium (StemCell Technologies) supplemented with 1% FBS, 1% penicillin/strep-
tomycin and cytokines (mouse IL-3, murine SCF, human FMS-like tyrosine kinase 3 ligand
[hFlt3L] and human IL-6) for 12 hours. After that, mHPCs were cultured in complete Stem-
Span medium during 7 to 14 days.
Quantification of CoQ9 and DMQ9 levels in MEFs and mHPCs
After lipid extraction from homogenized cultured MEFs and mHPCs, CoQ9 and DMQ9 levels
were determined via reversed-phase HPLC coupled to electrochemical (EC) detection [16].
The results were expressed in ng CoQ/mg prot and as DMQ9/CoQ9 ratio.
Gene expression analyses
Total cellular RNA from frozen cell pellets were extracted and electrophoresed in agarose
1.5% to check RNA integrity. RNA fromMEFs and mHPCs was extracted with Real Total
RNA Spin Plus Kit (Real). Total RNA was quantified by optical density at 260/280 nm and
was used to generate cDNA with High Capacity cDNA Reverse Transcription Kit (Applied
Biosystems). Amplification was performed with quantitative real-time PCR, by standard
curve method, with specific Taqman probes (from Applied Biosystems) for the targeted gene
mouse Coq9 (Mm00804236_m1) and the mouse Hprt probe as a standard loading control
(Mm01545399_m1).
Sample preparation andWestern blot analysis in cells
Cells were collected, washed twice with 1× PBS and homogenated in RIPA buffer freshly sup-
plemented with proteases inhibitors. To detect COQ7 protein, 60 μg of proteins from the sam-
ple extracts was electrophoresed in 12% Mini-PROTEAN TGX™ precast gels (Bio-Rad) using
the electrophoresis system mini-PROTEAN Tetra Cell (Bio-Rad). To detect COQ9 protein,
60 μg of proteins from sample extracts was prepared in XT sample buffer + XT-reducing agent
(Bio-Rad) and electrophoresed in a 10% Criterion™ XT precast gel (Bio-Rad) using MOPS run-
ning buffer and the electrophoresis system Criterion Cell (Bio-Rad). In all experiments, pro-
teins were transferred onto PVDF 0.45 μmmembranes using a mini Trans-blot Cell (Bio-rad)
or Trans-blot Cell (Bio-Rad) and probed with target antibodies. Protein-antibody interactions
were detected with peroxidase-conjugated horse anti-mouse, anti-rabbit or anti-goat IgG anti-
bodies using Amersham ECL™ Prime Western Blotting Detection Reagent (GE Healthcare,
Buckinghamshire, UK). Band quantification was carried out using an Image Station 2000R
(Kodak, Spain) and a Kodak 1D 3.6 software. COQ7 and COQ9 protein band intensity was
normalized to VDAC1, and the data expressed in terms of percent relative to wild-type mice
[4].
Flow cytometry
mHPCs were collected, washed with cold PBS containing 2% FBS and stained with fluoro-
chrome conjugated monoclonal antibodies anti-mouse CD11b-APC (BD-Bioscience) or anti-
mouse Ly-6A/E (Sca-1)-PE (eBioscience, San Diego, CA). Cells were acquired and analyzed on
a FACS Canto II flow cytometer (Becton Dickinson, Franklin Lakes, NJ) using the FACS Diva
software (BD Biosciences, Bedford, MA).
Assessment of mitochondrial function
Oxygen consumption rate (OCR) was measured in adherent fibroblasts with a XF24 Extracel-
lular Flux Analyzer (Seahorse Bioscience, Billerica, MA, USA). Each cell line was seeded in 6
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wells of a XF 24-well cell culture microplate (Seahorse Bioscience) at a density of 5×104 cells/
well in 250 μL of DMEM and incubated for 24 h at 37°C in 5% CO2 atmosphere. After replac-
ing the growth medium with 525 μL of bicarbonate-free DMEM pre-warmed at 37°C cells
were preincubated for 1 hour in a CO2 free incubator before starting the assay procedure
[17].
After baseline measurements, OCR was measured after sequentially adding to each well
75 μL of oligomycin, 75 μl of carbonyl cyanide 4-(trifluoromethoxy) phenylhy-drazone
(FCCP) and 75 μl of rotenone and antimycin, to reach working concentrations of 1 μM,
0,75 μM, and 1 μM, respectively [17].
Spare respiratory capacity was calculated according to the User Manual XF cell mito stress
test kit (SeaHorse Biosciences). Spare respiratory capacity = (Maximal respiration)—(Basal
Respiration). Non-mitochondrial respiration was subtracted in both maximal respiration and
basal respiration. Spare respiratory capacity provides an idea of the cells maximum ATP pro-
duction; therefore cells with a higher capacity have a greater ability to respond to stress.
Real time analysis of cells adhesion and growth
Adhesion and proliferation of Coq9+/+ -MEFs, Coq9R239X -MEFs and transduced Coq9R239X
-MEFs were measured using the xCelligence real-time cell analyzer system from Roche (Roche
Applied Science, Penzberg, Germany, www.roche.com). 1000 cells/well were added to 16-well
E-plates and analyzed as described previously [18]. Briefly, the E-plates loaded with the differ-
ent cells were placed on the device station in the incubator (5% CO2 at 37°C) for continuous
recording of impedance (a direct measure of the amount of cells adhered to the E-plate at each
time point), as reflected by cell index.
Statistical analysis
All statistical analyses were performed using the Prism 6 scientific software. Data are expressed
as the mean ± SD of four-six experiments per group. A one-way ANOVA with a Tukey post
hoc test was used to compare the differences between three experimental groups. A P-value of
0.05 was considered to be statistically significant.
Results
Overexpression of COQ9 in MEFs and mHPCs from Coq9R239Xmice
We generated a LV expressing Coq9 through the CMV promoter by insertion of the Coq9
cDNA into the CEWP vector backbone [13] (see M&M for details). MEFs and mHPCs derived
from Coq9R239X mice were transduced with CCoq9WP LVs particles at increasing MOI and
investigated whether transduced cells produce supraphysiological levels of Coq9mRNA and
COQ9 protein (Fig 1). In both cell models, the transduction with CCoq9WP produced levels of
Coq9mRNA 100–700 times higher than the levels observed in control Coq9+/+ cells (Fig 1A
and 1B). As a result, the levels of COQ9 protein were 10–30 times higher in transduced
Coq9R239X cells than in control Coq9+/+ cells (Fig 1C and 1D). Therefore, the CCoq9WP LV
was able to increase the Coq9mRNA and COQ9 protein beyond control values in both MEFs
and mHPCs from Coq9R239X mice.
Overexpression of COQ9 restores the normal function of the CoQ
biosynthetic pathway in MEFs and mHPCs from Coq9R239Xmice
COQ9 is needed for the stability and functional activity of the hydroxylase COQ7 [3, 4].
Thus, the Coq9R239X mouse model shows a severe reduction in the tissue levels of COQ7 and
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accumulation of DMQ9, the substrate of the reaction catalyzed by COQ7 (S1 Fig) [3, 4]. This
pattern was also observed in MEFs and mHPCs from Coq9R239X mice (Fig 2A and 2B). The
overexpression of COQ9 in transduced Coq9R239X MEFs and mHPCs induced an increase in
COQ7 levels, which were even higher than the levels observed in control cells (Fig 2A and 2B).
As a result, DMQ9 does not accumulate in CCoq9WP LV-transduced Coq9
R239X cells (Figs 3B,
3C, 3D, 3E, 4B, 4C, 4D and 4E) and the levels of CoQ9, the final product of the pathway, were
normalized (Figs 3A and 4A). In both wild-type and CCoq9WP LV-transduced Coq9R239X
mHPCs, we also observe higher levels of COQ7 and CoQ9 over the time (Figs 2B and 4A;
S1 and S2 Tables). This was in parallel to the differentiation of mHPCs during culture time
(S2 Fig).
Fig 1. Transduction with CCoq9WP vector increases the levels of Coq9mRNA and COQ9 protein in MEFs andmHPCs fromCoq9R239X mice.
Coq9 mRNA levels in MEFs (A) and mHPCs (B). COQ9 protein levels in MEFs (C) and mHPCs (D). Q: 1 hit in MEFs, 200 μl, non-concentrated; R: 1 hit
in MEFs, 100 μl, 10x-concentrated; S: 1 hit in MEFs, 25 μl, 10x-concentrated; T: 1 hit in MEFs, 5 μl, 10x-concentrated; U: 1 hit in HSCs, 400 μl, 23.5x-
concentrated; V: 2 hits in HSCs 400 μl, 23.5x-concentrated; 1: 7–9 days after transduction in HSCs; 2: 12–16 days after transduction in HSCs. Data are
expressed as mean ± SD. ***P < 0.001,Coq9R239X andCoq9R239X-CCoq9WP cells versusCoq9+/+ cells; +++P < 0.001,Coq9R239X-CCoq9WP cells versus
Coq9R239X cells; (one-way ANOVAwith a Tukey's post hoc test; n = 4–6 for each group). #: a non-specific band is detected inCoq9R239X cells with the
anti-COQ9 antibody.
doi:10.1371/journal.pone.0158344.g001
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Overexpression of COQ9 normalizes mitochondrial function and
enhances fitness in MEFs from Coq9R239Xmice
Skin fibroblasts of patients with primary CoQ10 deficiency show reduced activities of CoQ-
dependent mitochondrial complexes and decreased levels of ATP [16, 19–23]. Similarly, iso-
lated mitochondria from tissues of Coq9R239X show a reduction in mitochondrial respiration
[3, 4]. Therefore, we next investigated whether the increase of CoQ9 induces functional
changes in mitochondrial bioenergetics. We assessed the mitochondrial respiration in MEFs
by SeaHorse Analyzer. Coq9R239X MEFs show a decrease in the global oxygen consumption
rate and in the spare respiratory capacity (Fig 5A and 5B). Both alterations were normalized
after transduction of Coq9R239X MEFs with the CCoq9WP LV (Fig 5A and 5B). As a conse-
quence, cell growth was increased in CCoq9WP-transduced Coq9R239X compared to untrans-
duced Coq9R239X MEFs and also to wild-type MEFs (Fig 5C). The improved cell growth was
restricted to the first hours after plating, indicating that over-expression of COQ9 could
improve adhesion of MEFs to plastic and this could favor initial growth (see green square in
Fig 5C). After that moment, the growth rate was similar in the three experimental groups
(Fig 5C).
Fig 2. Overexpression of COQ9 inCoq9R239XMEFs andmHPCs increases the levels of COQ7. Levels of COQ7 in MEFs (A) and mHSCs (B). R: 1
hit in MEFs, 100 μl, 10x-concentrated; U: 1 hit in HPCs, 400 μl, 23.5x-concentrated; V: 2 hits in HPCs 400 μl, 23.5x-concentrated; 1: 7–9 days after
transduction in HSCs; 2: 12–16 days after transduction in HSCs. Data are expressed as mean ± SD. **P < 0.01,Coq9R239X andCoq9R239X-CCoq9WP
cells versusCoq9+/+ cells; ***P < 0.001,Coq9R239X andCoq9R239X-CCoq9WP cells versusCoq9+/+ cells; +P < 0.05,Coq9R239X-CCoq9WP cells versus
Coq9R239X cells; +++P < 0.001,Coq9R239X-CCoq9WP cells versusCoq9R239X cells; (one-way ANOVA with a Tukey's post hoc test; n = 4–6 for each
group).
doi:10.1371/journal.pone.0158344.g002
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Discussion
Mitochondrial encephalopathies are commonly caused by mutations in nDNA genes. Most of
these diseases are untreatable, other than by relieving certain symptoms. GT strategies aim for
restoring the function by direct transfer of genes encoding the wild-type protein into the CNS
[5, 8] or by using HSCs as Trojan horses to deliver the protein or the final product into the tar-
get tissue [7]. Both strategies require efficient and safe vectors able to deliver the therapeutic
gene to the CNS or to the HSCs. LVs have been used successfully for both strategies in preclini-
cal models and clinical studies [10]. Here, we have developed a LV (CCoq9WP) able to overex-
press Coq9mRNA and COQ9 protein in MEFs and mHPCs from Coq9R239X mice, an animal
model of mitochondrial encephalopathy. Importantly, the CoQ biosynthetic pathway and
mitochondrial function were normalized after LV treatment.
Fig 3. Lack of DMQ9 and increase of CoQ9 inCoq9R239X MEFs after transduction with CCoq9WP vector. Levels of CoQ9 (A) and DMQ9/CoQ9
ratio (B). Representative chromatographs of the three different groups (C-E). Q: 1 hit in MEFs, 200 μl, non-concentrated; R: 1 hit in MEFs, 100 μl, 10x-
concentrated; S: 1 hit in MEFs, 25 μl, 10x-concentrated; T: 1 hit in MEFs, 5 μl, 10x-concentrated. Data are expressed as mean ± SD. *P < 0.05,
Coq9R239X andCoq9R239X-CCoq9WP cells versusCoq9+/+ cells; ***P < 0.001,Coq9R239X andCoq9R239X-CCoq9WP cells versusCoq9+/+ cells;
+++P < 0.001,Coq9R239X-CCoq9WP cells versusCoq9R239X cells; (one-way ANOVA with a Tukey's post hoc test; n = 4–6 for each group).
doi:10.1371/journal.pone.0158344.g003
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In this study, we use MEFs and mHPCs from Coq9R239X mice. This mouse model shows
spongiform degeneration and severe reactive astrogliosis in the pons and diencephalon, result-
ing in early death [3, 4]. The cause of these pathological changes is a mitochondrial bioenerget-
ics impairment in the cerebrum due to a severe CoQ deficiency, which is caused by a mutation
in Coq9, also reported in patients with primary CoQ10 deficiency [23–25]. Overexpression
of Coq9 in MEFs and mHPCs was not only well tolerated but also increased the fitness of
Coq9R239X MEFs, probably due to their improvement in mitochondrial function and pyrimi-
dine biosynthesis, as well as a reduction in oxidative stress and apoptosis [16, 19, 20, 22, 26,
27]. Levels of COQ9 above of control levels were also achieved in skin fibroblasts of a patient
with a mutation in COQ9 treated with a lentivirus harboring Coq9 cDNA [23]. This gene is
essential for CoQ biosynthesis by encoding a protein, COQ9, which has been proposed to
be required for the stability of COQ7, a catalytic enzyme in the CoQ biosynthetic pathway
Fig 4. Lack of DMQ9 and increase of CoQ9 inCoq9R239X mHPCs after transduction with CCoq9WP vector. Levels of CoQ9 (A) and DMQ9/CoQ9
ratio (B). Representative chromatographs of the three different groups (C-E). U: 1 hit in HSCs, 400 μl, 23.5x-concentrated; V: 2 hits in HPCs 400 μl,
23.5x-concentrated; 1: 7–9 days after transduction in HPCs; 2: 12–16 days after transduction in HSCs. Data are expressed as mean ± SD. *P < 0.05,
Coq9R239X andCoq9R239X-CCoq9WP cells versusCoq9+/+ cells; **P < 0.01, Coq9R239X andCoq9R239X-CCoq9WP cells versusCoq9+/+ cells; ***P < 0.001,
Coq9R239X andCoq9R239X-CCoq9WP cells versusCoq9+/+ cells; +++P < 0.001,Coq9R239X-CCoq9WP cells versusCoq9R239X cells; (one-way ANOVAwith a
Tukey's post hoc test; n = 4–6 for each group).
doi:10.1371/journal.pone.0158344.g004
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[3, 4, 28, 29]. The results presented in this manuscript further confirm the interaction COQ9-
COQ7 since the overexpression of COQ9 in Coq9R239X cells induced an increase in the levels of
COQ7. Similar results were also obtained in human skin fibroblasts of a patient with COQ9
mutation [23]. The direct consequence of the increase of COQ7 in CCoq9WP-transduced
Coq9R239X cells is the complete reduction of DMQ9, the substrate of the reaction catalyzed by
this enzyme. However, even if the levels of COQ9 and COQ7 were higher in transduced cells
than in control cells (10 to 30 and 1 to 5 fold-increase, respectively), the levels of CoQ9, the
final product of the pathway, only increased 1.5 fold compared to wild-type levels. Similar
results were obtained in yeasts studies, where the overexpression of COQ8 (ADCK3) induced a
2.4 fold increase of CoQ levels compared to wild-type levels [30, 31]. These results reflect the
complex regulation of the CoQ biosynthetic pathway, which involves, at least, 12 different
Fig 5. Transduction with CCoq9WP vector restoresmitochondrial respiration and enhances fitness in MEFs fromCoq9R239X mice.Oxygen
consumption rate (OCR) profile (A), spare respiratory capacity (B) and cell index (C) in MEFs. Vertical arrows indicate the time of addition of oligomycin
(olyg), FCCP and rotenone/antymicin (Rot/Ant). 5×104 cells were plated in each well. Data are expressed as mean ± SD. *P < 0.05,Coq9R239X and
Coq9R239X-CCoq9WP cells versusCoq9+/+ cells; ++P < 0.01,Coq9R239X-CCoq9WP cells versusCoq9R239X cells; (one-way ANOVA with a Tukey's post hoc
test; n = 4–6 for each group).
doi:10.1371/journal.pone.0158344.g005
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proteins. Moreover, these proteins are organized in a multiprotein complex, which allow
channeling of labile/reactive intermediates, enhance catalytic efficiency, and provide a mecha-
nism for coordinative regulation of components [4, 32, 33].
An important result for future applications is the ability of the CCoq9WP LVs to over-
express up to 30 times the levels of COQ9 protein in Coq9R239X MEFs and mHPCs compared
to wild-type MEFs and mHPCs. These data open the possibility of using these LVs as a tool for
in vivo and ex vivo GT strategies for the treatment of CoQ deficiencies. Direct inoculation of
LVs (in vivo GT) has been proved to be efficient and safe for the treatment of several diseases
in animal models [34–36] and clinical studies [8]. As an alternative strategy, generation of
autologous HSCs transduced with CCoq9WP LVs (GM-HSCs) could be used as Trojan horses
to deliver COQ9 protein and/or CoQ lipid to different cell types distributed through the body,
including neurons. GM-HSC strategy has been proven to be efficient and safe not only in ani-
mal models of leukodystrophies [11, 12] and mitochondrial neurogastrointestinal encephalo-
myopathy (MNGIE) [37] but also in human clinical trials of both disorders [9, 10, 38].
In mHPCs, the levels of Coq9mRNA, COQ9 and COQ7 proteins and CoQ9 lipid were
higher in the second day of cell collection (12–16 days in culture) than those levels in the first
day of cell collection (7–9 days in culture). These differences may be caused by an increase on
mitochondrial mass, mitochondrial function and reactive oxygen species production during
cell differentiation [39–43], having, in that case, positive implication for the use of these cells in
the in vivo transplantation.
Future experiments using in vivo and ex vivo GT strategies with these LVs will provide evi-
dences of the best strategy for the treatment of these disorders. Protein transfer of mitochon-
drial proteins could be a problem for GM-HSCs but, at the same time, lipid transfer (CoQ9)
could be more efficient and achieve cross-correction of the CoQ-deficient cells. This is impor-
tant for the success of the in vivo therapy because our results in other mouse model of CoQ
deficiency (Coq9Q95X) suggest that reaching 50% of CoQ levels in cerebral cells would be
enough to avoid the encephalopathic phenotype [4]. Thus, it will be desirable to compare (or
combine) GM-HSCs with in vivo delivery of lentiviral vectors expressing the therapeutic pro-
tein as a possible treatment for mitochondrial encephalopathies.
In summary, the experimental approach used in this study show the correction of the bioen-
ergetics impartment in cells with primary CoQ deficiency using a LV. These results support the
evaluation of the CCoq9WP LV in a preclinical study in vivo.
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S1 Table. Time effect over the levels of the analyzed biomolecules in transduced mHPCs. U:
1 hit in HPCs, 400 μl, 23.5x-concentrated; 1: 7–9 days after transduction in HPCs; 2: 12–16
Gene Therapy for CoQ Deficiency
PLOS ONE | DOI:10.1371/journal.pone.0158344 June 24, 2016 11 / 14
days after transduction in HPCs. # P< 0.05, versus U1; ### P< 0.05, versus U1; (Student's t
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